Hayashi H, Nutting D F, Fujimoto K, Cardelli J A, Black D, Tso P
Department of Physiology, Louisiana State University Medical Center, Shreveport 71130.
J Lipid Res. 1990 Sep;31(9):1613-25.
Intestinal lipid absorption is associated with marked increases in the synthesis and secretion of apolipoprotein A-IV (apoA-IV) by the small intestine. Whether the increased intestinal apoA-IV synthesis and secretion results from increased fat uptake, increased cellular triglyceride (TG) content, or increased secretion of TG-rich lipoproteins by the enterocytes is unknown. Previous work from this laboratory has shown that a hydrophobic surfactant, Pluronic L-81 (L-81), is a potent inhibitor of intestinal formation of chylomicrons (CM), without reducing fat uptake or re-synthesis to TG. Furthermore, this inhibition can be reversed quickly by the cessation of L-81 infusion. Thus L-81 offers a unique opportunity to study the relationship between lymphatic TG, apoA-I and A-IV secretion. In this study, we studied the lymphatic transport of TG, apoA-I, and apoA-IV during both the inhibitory phase (L-81 infused together with lipid) and the subsequent unblocking phase (saline infusion). Two groups of lymph fistula rats were used, the control and the experimental rats. In the experimental rats, a phosphate-buffered taurocholate-stabilized emulsion containing 40 mumol [3H]triolein, 7.8 mumol of phosphatidylcholine, and 1 mg L-81 per 3 ml was infused at 3 ml/h for 8 h. This was then replaced by glucose-saline infusion for an additional 12 h. The control rats received the same lipid emulsion as the experimental rats, but without L-81 added, for 8 h. Lymph lipid was determined both by radioactivity and by glyceride-glycerol determination, and the apoA-I and apoA-IV concentrations were determined by rocket electroimmunophoresis assay. L-81 inhibited the rise in lymphatic lipid and apoA-IV output in the experimental rats after the beginning of lipid + L-81 infusion. Upon cessation of L-81 infusion, the mucosal lipid accumulated as a result of L-81 treatment was rapidly cleared into lymph as CM. This was associated with a marked increase in apoA-IV output; the maximal output was about 3 times that of the fasting level. There was a time lag of 4-5 h between the peak lymph lipid output and the peak lymph apoA-IV output during the unblocking phase in the experimental rats. There was also a comparable time lag between the maximal lipid and apoA-IV outputs in the control animals. Incorporation studies using [3H]leucine showed that apoA-IV synthesis was not stimulated during lipid + L-81 infusion, perhaps explaining the lack of increase in lymphatic A-IV secretion.(ABSTRACT TRUNCATED AT 400 WORDS)
肠道脂质吸收与小肠载脂蛋白A-IV(apoA-IV)合成及分泌的显著增加相关。肠道apoA-IV合成及分泌增加是由于脂肪摄取增加、细胞内甘油三酯(TG)含量增加,还是肠细胞分泌富含TG的脂蛋白增加,目前尚不清楚。本实验室之前的研究表明,一种疏水性表面活性剂普朗尼克L-81(L-81)是肠道乳糜微粒(CM)形成的有效抑制剂,且不会降低脂肪摄取或向TG的再合成。此外,停止输注L-81后,这种抑制作用可迅速逆转。因此,L-81为研究淋巴TG、apoA-I和A-IV分泌之间的关系提供了独特的机会。在本研究中,我们研究了在抑制期(L-81与脂质一起输注)和随后的解除阻断期(输注生理盐水)期间TG、apoA-I和apoA-IV的淋巴转运情况。使用了两组淋巴瘘大鼠,即对照大鼠和实验大鼠。对实验大鼠,以3 ml/h的速度输注一种含40 μmol [3H]三油酸甘油酯、7.8 μmol磷脂酰胆碱且每3 ml含1 mg L-81的磷酸盐缓冲牛磺胆酸盐稳定乳液,持续8小时。然后换成葡萄糖生理盐水输注,再持续12小时。对照大鼠接受与实验大鼠相同的脂质乳液,但不添加L-81,持续8小时。通过放射性和甘油酯-甘油测定法测定淋巴脂质,通过火箭免疫电泳法测定apoA-I和apoA-IV浓度。在脂质+L-81输注开始后,L-81抑制了实验大鼠淋巴脂质和apoA-IV输出的增加。停止输注L-81后,L-81处理导致积累的黏膜脂质作为CM迅速清除到淋巴中。这与apoA-IV输出的显著增加相关;最大输出约为空腹水平的3倍。在实验大鼠的解除阻断期,淋巴脂质输出峰值与淋巴apoA-IV输出峰值之间存在4 - 5小时的时间滞后。对照动物的最大脂质和apoA-IV输出之间也存在类似的时间滞后。使用[3H]亮氨酸的掺入研究表明,在脂质+L-81输注期间,apoA-IV合成未受到刺激,这可能解释了淋巴A-IV分泌缺乏增加的原因。(摘要截短至400字)